Skip to main
- Resource Type:
- Industry Symposia
Lunch Symposium: Neoadjuvant, Adjuvant, or Both: How to Solve the Puzzle of Perioperative Immunotherapy, Individualize Treatment Plans, and Improve Cure Rates in Resectable NSCLC | Supported by: Bristol Myers Squibb Genentech and Merck & Co., Inc. | CME p
May 6, 2023